-+ 0.00%
-+ 0.00%
-+ 0.00%

Nanjing Leads Biolabs FY26 H1 loss widens 33.4% to RMB 221.93 million; revenue swings to RMB 35.97 million

PUBT·08/31/2026 08:32:41
Listen to the news
Nanjing Leads Biolabs FY26 H1 loss widens 33.4% to RMB 221.93 million; revenue swings to RMB 35.97 million
  • Nanjing Leads Biolabs posted revenue of RMB 35.97 million, compared with no revenue a year earlier.
  • Net loss widened 33.4% to RMB 221.93 million, while R&D costs climbed 44.9% to RMB 191.02 million.
  • Administrative expenses rose 15.5% to RMB 41.37 million on higher staff costs and post-listing compliance, partly offset by lower share-based pay.
  • Cash and time deposits fell to RMB 1.24 billion from RMB 1.55 billion at Dec. 31, 2025.
  • Pipeline update: LBL-024 NDA for previously treated advanced EP-NEC was accepted by China’s NMPA on Aug. 21, 2026, targeting H1 2027 approval.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanjing Leads Biolabs Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260831-12307909), on August 31, 2026, and is solely responsible for the information contained therein.